However, the lack of correlation between calcidiol and PTH plasma levels in the different evaluations along the period of treatment with rhGH together with a steady increase, with no seasonal variations, of PTH (not reaching levels of hyperparathyroidism) point out that the increase of PTH levels in these patients is secondary to a biological action of GH; the purpose of this action would be to boost the acquisition of bone mass and, consequently, growth in length. The gene discussed is GH1; the disease is hyperparathyroidism.